* **Celiac Disease Full Text Screening Tool**

1. Should the study have been rejected at abstract screening? If yes, please state the reason.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Yes (STOP), submit form  Specify:   |  | | --- | | Not English language | | Not human | | Not about celiac disease (CD) | | Not about diagnosis of CD or under-diagnosis of CD | | No original data - letter, commentary, editorial, etc. | | Individual case report | | Prevalence, outside U.S. | | Diagnostic method outside the scope of study. (Diagnostic methods included in the KQs are Endomysial antibodies (EmA) test, Anti-tissue Transglutaminase (tTG) test, Deamidated Gliadin Peptide (DGP) antibody, HLA typing, video capsule endoscopy, and endoscopy with biopsy) | | Test processing issue (E.g., PCR vs. other method) | | Serology Only | | Pre dates systematic review (SR) on topic | |  | |
| No |
|  |

2. Does the article address Key Question 4 - adverse effects of invasive methods (endoscopy with biopsy, video capsule endoscopy)?

|  |
| --- |
| Yes (STOP), submit form - study will be included |
| No |
|  |

3. Does the article address Key Question 2 - how the accuracy of duodenal biopsy varies by MD training, method, or length of gluten ingestion?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Yes (STOP), submit form - study will be included  If yes, indicate which one:   |  | | --- | | Pathologist characteristics, i.e. level of experience or specific training | | Method, i.e. type or number of specimens | | Length of time ingesting gluten before diagnostic testing | | Exclude study (indicate reason) |  | |
| No |
|  |

4. Does the article address Key Question 1 or Key Question 3 - assess the accuracy or effectiveness (e.g. outcomes) of any of the following? (check all that apply)

|  |
| --- |
| Endomysial antibodies (EmA) IgA test |

|  |
| --- |
| Anti-tissue transglutaminase (tTG) IgA test |
| EmA IgG, tTG IgG, and DGP IgG tests for IgA deficient individuals |
| Deamidated Gliadin Peptide (DGP) IgA Antibodies |
| HLA-DQ2 or HLA-DQ8 |
| Video capsule endoscopy |
| None of the above (STOP), submit form - study will be excluded |
| Does not assess accuracy or effectiveness e.g. only prevalence, test processing, etc. (STOP), submit form - study will be excluded |

5. If this is an accuracy study:

Are the tests compared to biopsy?

|  |
| --- |
| Yes |
| No (STOP), submit form - study will be excluded |
|  |

Did ALL subjects undergo both the "intervention" diagnostic method and the "reference" standard (usually biospy)?

(i.e. everyone who received a serological test should get biopsy too, regardless of whether the test was negative or positive)

|  |
| --- |
| Yes |
| No (STOP), submit form - study will be excluded |
|  |

6. What is the sample size?



7. Was a consecutive or random sample of patients enrolled?

|  |
| --- |
| Yes |
| No |
| Unclear |
|  |

8. Does the article present results specific to the following populations? (check all that apply)

|  |
| --- |
| Children, under age 24 months vs. older children & adolescents |
| Adults (aged 18+) |
| Ethnic or geographic populations (Specify) |  |
| Low socioeconomic status (SES) |  |
| IgA deficient |  |
| Previously negative for CD |  |
| With signs and symptoms of CD (i.e., diarrhea, nutrional deficits, etc.) |  |

|  |  |
| --- | --- |
| With type 1 diabetes |  |
| With auto-immune disease |  |
| With Turner's syndrome |  |
| With trisomy 21/Down Syndrome |  |
| With family history |  |
| Other special population (Specify) |  |
| General population, no special populations |  |

9. Does the article need further discussion?

|  |
| --- |
| Yes |
| No |

Notes:

